MARKET

BLRX

BLRX

Biolinerx
NASDAQ
3.170
+0.013
+0.42%
After Hours: 3.150 -0.02 -0.63% 16:05 05/09 EDT
OPEN
3.160
PREV CLOSE
3.157
HIGH
3.350
LOW
3.133
VOLUME
6.28K
TURNOVER
--
52 WEEK HIGH
35.60
52 WEEK LOW
2.300
MARKET CAP
11.80M
P/E (TTM)
-0.6865
1D
5D
1M
3M
1Y
5Y
1D
BioLineRx Ltd., Merck Granted U.S. Patent #12291570 Treatment of metastatic pancreatic adenocarcinoma
Benzinga · 5d ago
Weekly Report: what happened at BLRX last week (0428-0502)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 05/02 21:05
Weekly Report: what happened at BLRX last week (0421-0425)?
Weekly Report · 04/28 10:21
Weekly Report: what happened at BLRX last week (0414-0418)?
Weekly Report · 04/21 10:21
Weekly Report: what happened at BLRX last week (0407-0411)?
Weekly Report · 04/14 10:15
Weekly Report: what happened at BLRX last week (0331-0404)?
Weekly Report · 04/07 10:14
Xiaomi, Bioline RX, Snowflake, Broadcom, Tesla: Trending by Analysts
TipRanks · 04/05 09:01
More
About BLRX
More
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Recently
Symbol
Price
%Change

Webull offers BioLine RX Ltd - ADR stock information, including NASDAQ: BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.